Developing a Scalable Manufacturing Process for an Oral Bacteriophage Product that Prevents Cholera

开发预防霍乱的口服噬菌体产品的可扩展制造工艺

基本信息

  • 批准号:
    10086723
  • 负责人:
  • 金额:
    $ 5.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-12-15 至 2020-11-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Cholera is an acute and severe disease caused by the bacterium Vibrio cholerae that is spread primarily through contaminated water sources due to a lack of adequate sanitation infrastructure. The World Health Organization estimates that there are at least 3 million cases globally per year, 40 percent of which are spread through household transmission. Current prevention methods require significant investment of resources and time for efficacy, but household contacts of cholera patients often present with cholera symptoms two to three days after the initial patient becomes sick. In addition, the preventive use of antibiotics is not recommended due to widespread resistance and the known negative consequences of dysbiosis. There is a pressing need to develop a targeted clinical intervention to prevent the community spread of cholera using a rapid prophylactic treatment. The goal of the proposed studies is to demonstrate feasibility of developing our phage-based clinical intervention, ProphaLytic-VC, to prevent the community spread of cholera. ProphaLytic-VC is an orally administered cocktail of three different phages known as ICP1, ICP2, and ICP3. To date, these are the only three virulent phages found in association with epidemic strains of cholera. Detailed genomic and phenotypic characterization each of the phages has been conducted by the academic partner, resulting in genome sequences, annotation, and identification of the host receptors. The combination of the three has been evaluated to demonstrate potency in reducing colonization of V. cholerae and prevention of cholera symptoms in two animal models of V. cholerae colonization and pathogenesis. Here, we propose studies to optimize a robust and scalable manufacturing process for ProphaLytic-VC, as there is currently little manufacturing experience in the USA due to the novel nature of the product. We will construct two phage production strains, develop a scalable phage production and purification scheme, and evaluate any potential local of systemic toxicity. At the successful conclusion of Phase I, we will have a resultant Master Phage Stock (MPS) of ProphaLytic-VC from an optimized large-scale production scheme that is potent against V. cholerae and safe with repeated oral administration. STTR Phase II funding will be used to fund further activities to generate a working phage seed stock from the MPS to proceed with a Phase I clinical trial.
项目摘要 霍乱是由霍乱弧菌引起的一种急性和严重的疾病, 由于缺乏足够的卫生基础设施,这些人通过受污染的水源生活。世界卫生 该组织估计,全球每年至少有300万例病例,其中40%是传播性的。 通过家庭传播。目前的预防方法需要大量的资源投资, 不过,与霍乱病人有家居接触的人士,往往会出现两至三个霍乱病征, 在第一个病人生病后的几天。此外,不建议预防性使用抗生素 由于广泛的耐药性和已知的生态失调的负面后果。迫切需要 制定有针对性的临床干预措施,使用快速预防剂预防霍乱的社区传播 治疗所提出的研究的目标是证明开发我们的基于噬菌体的临床治疗的可行性。 预防性干预,即预防性VC,以防止霍乱的社区传播。ProphaLytic-VC是一种口服 三种不同的药物的混合物,称为ICP 1,ICP 2和ICP 3。到目前为止,这些是唯一的 发现的与霍乱流行株有关的三种有毒的细菌。详细的基因组和表型 每一个基因组的特征都是由学术合作伙伴进行的, 序列、注释和宿主受体的鉴定。这三者的结合, 评价以证明减少霍乱弧菌定殖和预防霍乱症状的效力 在两种动物模型的霍乱弧菌定植和发病机制。在这里,我们提出了研究,以优化一个 ProphaLytic-VC的稳健和可扩展的生产工艺,因为目前几乎没有生产 由于产品的新颖性,在美国的经验。我们将构建两个噬菌体生产菌株, 开发可扩展的噬菌体生产和纯化方案,并评估任何潜在的局部或系统性 毒性在第一阶段成功结束时,我们将得到的主噬菌体储备(MPS)为 ProphaLytic-VC来自优化的大规模生产方案,对霍乱弧菌有效且安全 反复口服给药。STTR第二阶段的资金将用于资助进一步的活动, 来自MPS的工作噬菌体种子储备以进行I期临床试验。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Andrew Camilli其他文献

Andrew Camilli的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Andrew Camilli', 18)}}的其他基金

Molecular Genetics of Basic Cell Function
基本细胞功能的分子遗传学
  • 批准号:
    10408892
  • 财政年份:
    2022
  • 资助金额:
    $ 5.5万
  • 项目类别:
Molecular Genetics of Basic Cell Function
基本细胞功能的分子遗传学
  • 批准号:
    10624455
  • 财政年份:
    2022
  • 资助金额:
    $ 5.5万
  • 项目类别:
Targeting antibiotic resistance genes in Vibrio cholerae using a phage-encoded CRISPR-Cas system to improve efficacy of phage prophylaxis
使用噬菌体编码的 CRISPR-Cas 系统靶向霍乱弧菌中的抗生素抗性基因,以提高噬菌体预防的功效
  • 批准号:
    10320480
  • 财政年份:
    2021
  • 资助金额:
    $ 5.5万
  • 项目类别:
Product optimization to commercialize an oral bacteriophage cocktail that prevents cholera in real-world settings
产品优化,以将可在现实环境中预防霍乱的口服噬菌体混合物商业化
  • 批准号:
    10555220
  • 财政年份:
    2018
  • 资助金额:
    $ 5.5万
  • 项目类别:
Product optimization to commercialize an oral bacteriophage cocktail that prevents cholera in real-world settings
产品优化,以将可在现实环境中预防霍乱的口服噬菌体混合物商业化
  • 批准号:
    10349544
  • 财政年份:
    2018
  • 资助金额:
    $ 5.5万
  • 项目类别:
Developing a Scalable Manufacturing Process for an Oral Bacteriophage Product that Prevents Cholera
开发预防霍乱的口服噬菌体产品的可扩展制造工艺
  • 批准号:
    10097213
  • 财政年份:
    2018
  • 资助金额:
    $ 5.5万
  • 项目类别:
Developing a novel strategy to uncover vaccine targets in bacterial pathogens
开发一种新策略来发现细菌病原体中的疫苗靶点
  • 批准号:
    8990816
  • 财政年份:
    2015
  • 资助金额:
    $ 5.5万
  • 项目类别:
Developing a novel strategy to uncover vaccine targets in bacterial pathogens
开发一种新策略来发现细菌病原体中的疫苗靶点
  • 批准号:
    8891081
  • 财政年份:
    2015
  • 资助金额:
    $ 5.5万
  • 项目类别:
Impact of Bacteriophages on Virulence and Transmission of Vibrio cholerae
噬菌体对霍乱弧菌毒力和传播的影响
  • 批准号:
    10548231
  • 财政年份:
    2003
  • 资助金额:
    $ 5.5万
  • 项目类别:
Study of transmissible forms of Vibrio cholerae
霍乱弧菌传播形式的研究
  • 批准号:
    7048469
  • 财政年份:
    2003
  • 资助金额:
    $ 5.5万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.5万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 5.5万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 5.5万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 5.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 5.5万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 5.5万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 5.5万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 5.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 5.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 5.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了